
Eleonora Virgilio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2416077/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study. Multiple Sclerosis Journal, 2022, 28, 1034-1040.	3.0	37
2	The effect of air pollution on COVIDâ€19 severity in a sample of patients with multiple sclerosis. European Journal of Neurology, 2022, 29, 535-542.	3.3	8
3	COVID-19 Severity in Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	57
4	Neurological emergency at the COVID-19 pandemic: report from a referral hospital in Eastern Piedmont, Italy. Neurological Sciences, 2022, 43, 2195.	1.9	2
5	Susac Syndrome: an uncommon cause of impaired vision. Neurological Sciences, 2022, 43, 3919-3922.	1.9	2
6	Cerebrospinal fluid biomarkers and cognitive functions at multiple sclerosis diagnosis. Journal of Neurology, 2022, 269, 3249-3257.	3.6	20
7	The Role of Tau beyond Alzheimer's Disease: A Narrative Review. Biomedicines, 2022, 10, 760.	3.2	12
8	Early Successful Eye Movement Desensitization and Reprocessing (EMDR) Therapy for Verbal Memory Impairment in an Adjustment Disorder: A Case Report in a Newly-Diagnosed Multiple Sclerosis Patient. Reports, 2022, 5, 17.	0.5	1
9	Bilateral Facial Palsy as the Onset of Neurosarcoidosis: A Case Report and a Revision of Literature. NeuroSci, 2022, 3, 321-331.	1.2	1
10	Paraneoplastic neuromyelitis optica spectrum disorders: a case series. Neurological Sciences, 2021, 42, 2519-2522.	1.9	7
11	The Yin-Yang of osteopontin in nervous system diseases: damage versus repair. Neural Regeneration Research, 2021, 16, 1131.	3.0	29
12	Efficacy of Cannabinoids on Spasticity and Chronic Pain in a Patient with Co-occurrence of Multiple Sclerosis and Neurofibromatosis Type 1. European Journal of Case Reports in Internal Medicine, 2021, 8, 002424.	0.4	0
13	DMTs and Covidâ€19 severity in MS: a pooled analysis from Italy and France. Annals of Clinical and Translational Neurology, 2021, 8, 1738-1744.	3.7	86
14	Cerebrospinal Tau levels as a predictor of early disability in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 56, 103231.	2.0	13
15	Benign COVID-19 in an aggressive case of aquaporin-4 Neuromyelitis optica treated with tocilizumab. Journal of the Neurological Sciences, 2021, 429, 119867.	0.6	0
16	CSF Tau protein correlates with cognitive impairment in multiple sclerosis patients at diagnosis. Journal of the Neurological Sciences, 2021, 429, 117752.	0.6	0
17	Cannabinoids efficacy in vanishing white matter disease: A case report. Journal of the Neurological Sciences, 2021, 429, 118270.	0.6	0
18	Serum Vitamin D as a Marker of Impaired Information Processing Speed and Early Disability in Multiple Sclerosis Patients. Brain Sciences, 2021, 11, 1521.	2.3	14

Eleonora Virgilio

#	Article	IF	CITATIONS
19	Contribution of Rare and Low-Frequency Variants to Multiple Sclerosis Susceptibility in the Italian Continental Population. Frontiers in Genetics, 2021, 12, 800262.	2.3	3
20	Intrathecal kappa free light chains as markers for multiple sclerosis. Scientific Reports, 2020, 10, 20329.	3.3	29
21	Cannabinoids in multiple sclerosis: A neurophysiological analysis. Acta Neurologica Scandinavica, 2020, 142, 333-338.	2.1	6
22	K Index is a Reliable Marker of Intrathecal Synthesis, and an Alternative to IgG Index in Multiple Sclerosis Diagnostic Work-Up. Journal of Clinical Medicine, 2019, 8, 446.	2.4	27
23	Kappa free light chains could predict early disease course in multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 30, 81-84.	2.0	23
24	MOG-antibody demyelinating diseases: a case of post-partum severe rhombencephalitis and transverse myelitis. Multiple Sclerosis and Related Disorders, 2018, 21, 9-10.	2.0	13